Literature DB >> 29992463

Multiparametric MRI for prostate cancer: a national survey of patterns of practice among radiation oncologists in Spain.

F Couñago1, G Sancho2, A Gómez-Iturriaga3, I Henríquez4.   

Abstract

PURPOSE: To investigate patterns of practice among Spanish radiation oncologists in the use of multiparametric magnetic resonance imaging (mpMRI) for the treatment of prostate cancer (PCa). We evaluated (1) access to mpMRI, (2) current clinical practices, and (3) physician expectations of mpMRI.
METHODS: Cross-sectional survey of 118 radiation oncologists at 75 Radiation Oncology (RO) departments in Spain.
RESULTS: A total of 55 radiation oncologists from 52 RO departments (52/75; 69%) completed the survey. Prostate mpMRI is performed at 94.5% of the centres that provided data. The most common indications for mpMRI in routine clinical practice were: (1) detection/localization of the tumour prior to second biopsy (82.7%), (2) cancer staging (80.8%), and (3) detection of recurrence after definitive treatment (80.8%). Most respondents (72.7%) reported modifying the primary radiotherapy treatment when mpMRI findings indicate a more advanced T stage with a resultant change in the risk group. Most respondents (90.5%) treat macroscopic local recurrence after prostatectomy with high doses, ranging from 71 to 83 Gy; in 37.7% of cases, the full dose is delivered to the entire prostate bed. In pelvic nodal recurrence, more than half (59.3%) of the respondents reported performing elective pelvic radiotherapy, including the prostate bed, with a boost to the involved nodes.
CONCLUSIONS: This survey shows that prostate mpMRI is routinely used by radiation oncologists in Spain in a wide range of clinical scenarios. The findings reported here underscore the need to standardize treatment protocols for definitive and salvage radiotherapy in patients evaluated with mpMRI.

Entities:  

Keywords:  Magnetic resonance imaging; Prostate cancer; Radiation oncologists; Survey

Mesh:

Year:  2018        PMID: 29992463     DOI: 10.1007/s12094-018-1919-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  24 in total

1.  Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain.

Authors:  A Gómez Caamaño; A Zapatero; J López Torrecilla; X Maldonado
Journal:  Clin Transl Oncol       Date:  2015-11-30       Impact factor: 3.405

2.  A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer.

Authors:  Daniel E Spratt; Robert T Dess; Zachary S Zumsteg; Daniel W Lin; Phuoc T Tran; Todd M Morgan; Emmanuel S Antonarakis; Paul L Nguyen; Charles J Ryan; Howard M Sandler; Matthew R Cooperberg; Edwin Posadas; Felix Y Feng
Journal:  Eur Urol       Date:  2017-07-14       Impact factor: 20.096

3.  Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Authors:  William U Shipley; Wendy Seiferheld; Himanshu R Lukka; Pierre P Major; Niall M Heney; David J Grignon; Oliver Sartor; Maltibehn P Patel; Jean-Paul Bahary; Anthony L Zietman; Thomas M Pisansky; Kenneth L Zeitzer; Colleen A F Lawton; Felix Y Feng; Richard D Lovett; Alexander G Balogh; Luis Souhami; Seth A Rosenthal; Kevin J Kerlin; James J Dignam; Stephanie L Pugh; Howard M Sandler
Journal:  N Engl J Med       Date:  2017-02-02       Impact factor: 91.245

Review 4.  Magnetic resonance imaging basics for the prostate brachytherapist.

Authors:  Jihong Wang; Kari Tanderup; Adam Cunha; Antonio L Damato; Gil'ad N Cohen; Rajat J Kudchadker; Firas Mourtada
Journal:  Brachytherapy       Date:  2017-04-07       Impact factor: 2.362

5.  Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer.

Authors:  Alfonso Gomez-Iturriaga; Francisco Casquero; Jose Ignacio Pijoan; Juanita Crook; Arantza Urresola; Ana Ezquerro; Geert M Villeirs; Alberto Bossi; Jon Cacicedo; David Buchser; Pedro Bilbao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-04-22       Impact factor: 7.038

6.  Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome.

Authors:  Jehonathan H Pinthus; Maciej Witkos; N E Fleshner; Joan Sweet; Andrew Evans; M A Jewett; Murray Krahn; Shabir Alibhai; John Trachtenberg
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

Review 7.  Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis.

Authors:  Ivo G Schoots; Monique J Roobol; Daan Nieboer; Chris H Bangma; Ewout W Steyerberg; M G Myriam Hunink
Journal:  Eur Urol       Date:  2014-12-03       Impact factor: 20.096

8.  Current practice and access to prostate MR imaging in France.

Authors:  R Renard-Penna; O Rouvière; P Puech; C Borgogno; L Abbas; C Roy; M Claudon; J-M Correas; L Cormier; G Ploussard; A Mejean; S Tezenas-du-Montcel; F Rozet
Journal:  Diagn Interv Imaging       Date:  2016-07-20       Impact factor: 4.026

9.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

Review 10.  Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know.

Authors:  Felipe Couñago; Gemma Sancho; Violeta Catalá; Diana Hernández; Manuel Recio; Sara Montemuiño; Jhonathan Alejandro Hernández; Antonio Maldonado; Elia Del Cerro
Journal:  World J Clin Oncol       Date:  2017-08-10
View more
  1 in total

1.  Multiparametric magnetic resonance imaging-guided salvage radiotherapy in prostate cancer.

Authors:  Felipe Couñago; Ana Aurora Díaz Gavela; Gemma Sancho; Irene Ortiz; Francisco José Marcos; Manuel Recio; Julio Fernández; Raquel Cano; Mar Jiménez; Israel J Thuissard; David Sanz-Rosa; Juan Castro Nováis; Eduardo Pardo; Yolanda Molina; Hugo Pérez García; Elia Del Cerro
Journal:  Rep Pract Oncol Radiother       Date:  2019-08-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.